If approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, with the option to self-administer, PiaSky may provide...
Positive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show early and sustained vision improvements, which are non-inferior to...
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment...
Roche announced the launch of its new analytical units, cobas c 703 and cobas ISE neo, for the cobas pro integrated solutions, in countries accepting the CE mark. The cobas pro integrated solutions is a scalable and modular diagnostic platform designed for high-volume laboratories. The cobas c 703 and cobas ISE neo analytical units offer cutting-edge feature
The cobas® c 703 and cobas® ISE neo analytical units, deliver higher testing capacity and increased automation helping to improve laboratory workflows and advance patient care.The new cobas c 703...
US FDA approves Roche`s drug for a chronic blood disorder
Data released earlier this month showed that across nearly 600 cancer patient groups, Roche was rated as having the best reputation among pharmas in 2023. Now, PatientView has offered an even deeper dive into those findings, breaking out patient sentiments by several cancer types.
Roche announced that its whole-slide imaging system, the Roche Digital Pathology Dx (VENTANA DP 200), has received 510(k) clearance from the United States Food and Drug Administration (FDA). The system is intended to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
Roche partners with Ascidian Therapeutics to develop gene therapies
Roche’s up-and-coming Columvi has demonstrated it could save lives when used as a second-line therapy in diffuse large B-cell lymphoma (DLBCL). But the Swiss pharma still finds itself fielding questions about the bispecific drug’s market potential thanks to an imbalance noticed in the phase 3 data.